Nurix Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Nurix Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Nov 30, 2023 | $76.99M | Feb 15, 2024 |
| FY2023 | Nov 30, 2022 | $38.63M | Feb 15, 2024 |
| FY2022 | Nov 30, 2021 | $29.75M | Feb 9, 2023 |
| FY2020 | Nov 30, 2020 | $6.69M | Feb 16, 2021 |
| FY2020 | Aug 31, 2020 | $4.09M | Feb 16, 2021 |
| FY2020 | May 31, 2020 | $4.18M | Feb 16, 2021 |
| FY2020 | Feb 29, 2020 | $2.86M | Feb 16, 2021 |
| FY2020 | Nov 30, 2019 | $1.86M | Feb 16, 2021 |
| FY2020 | Aug 31, 2019 | $10.58M | Feb 16, 2021 |
| FY2020 | May 31, 2019 | $9.44M | Feb 16, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $83.98M | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $54.55M | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | $76.99M | Jan 28, 2026 |
| FY2024 | Nov 30, 2022 | $38.63M | Jan 28, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | ($264.46M) | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | ($193.57M) | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | ($143.95M) | Jan 28, 2026 |
| FY2024 | Nov 30, 2022 | ($180.36M) | Jan 28, 2025 |
| FY2022 | Nov 30, 2021 | ($117.19M) | Feb 9, 2023 |
| FY2020 | Nov 30, 2020 | ($19.91M) | Feb 16, 2021 |
| FY2020 | Aug 31, 2020 | ($18.52M) | Feb 16, 2021 |
| FY2020 | May 31, 2020 | $7.58M | Feb 16, 2021 |
| FY2020 | Feb 29, 2020 | ($12.39M) | Feb 16, 2021 |
| FY2020 | Nov 30, 2019 | ($13.52M) | Feb 16, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | ($285.67M) | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | ($213.03M) | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | ($155.06M) | Jan 28, 2026 |
| FY2024 | Nov 30, 2022 | ($183.87M) | Jan 28, 2025 |
| FY2022 | Nov 30, 2021 | ($117.89M) | Feb 9, 2023 |
| FY2021 | Nov 30, 2020 | ($64.98M) | Jan 28, 2022 |
| FY2021 | Nov 30, 2019 | ($22.24M) | Jan 28, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $316.90M | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $221.63M | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | $189.15M | Jan 28, 2026 |
| FY2024 | Nov 30, 2022 | $184.50M | Jan 28, 2025 |
| FY2022 | Nov 30, 2021 | $116.43M | Feb 9, 2023 |
| FY2021 | Nov 30, 2020 | $66.49M | Jan 28, 2022 |
| FY2021 | Nov 30, 2019 | $45.03M | Jan 28, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | ($249.47M) | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | ($172.58M) | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | ($81.37M) | Jan 28, 2026 |
| FY2024 | Nov 30, 2022 | ($159.81M) | Jan 28, 2025 |
| FY2022 | Nov 30, 2021 | ($84.37M) | Feb 9, 2023 |
| FY2021 | Nov 30, 2020 | ($80.0K) | Jan 28, 2022 |
| FY2021 | Nov 30, 2019 | $601.0K | Jan 28, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $14.00M | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $9.27M | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | $8.40M | Jan 28, 2026 |
| FY2024 | Nov 30, 2022 | $12.24M | Jan 28, 2025 |
| FY2022 | Nov 30, 2021 | $5.66M | Feb 9, 2023 |
| FY2021 | Nov 30, 2020 | $4.55M | Jan 28, 2022 |
| FY2021 | Nov 30, 2019 | $1.65M | Jan 28, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $688.14M | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $669.34M | Jan 28, 2026 |
| FY2024 | Nov 30, 2023 | $355.60M | Jan 28, 2025 |
| FY2023 | Nov 30, 2022 | $416.76M | Feb 15, 2024 |
| FY2022 | Nov 30, 2021 | $476.77M | Feb 9, 2023 |
| FY2021 | Nov 30, 2020 | $396.34M | Jan 28, 2022 |
| FY2020 | Nov 30, 2019 | $44.05M | Feb 16, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $149.39M | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $142.35M | Jan 28, 2026 |
| FY2024 | Nov 30, 2023 | $155.11M | Jan 28, 2025 |
| FY2023 | Nov 30, 2022 | $113.06M | Feb 15, 2024 |
| FY2022 | Nov 30, 2021 | $134.47M | Feb 9, 2023 |
| FY2021 | Nov 30, 2020 | $106.07M | Jan 28, 2022 |
| FY2020 | Nov 30, 2019 | $53.57M | Feb 16, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $538.75M | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $526.99M | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | $200.49M | Jan 28, 2026 |
| FY2025 | Nov 30, 2022 | $303.70M | Jan 28, 2026 |
| FY2024 | Nov 30, 2021 | $342.30M | Jan 28, 2025 |
| FY2022 | Nov 30, 2020 | $290.27M | Feb 9, 2023 |
| FY2021 | Nov 30, 2019 | ($57.71M) | Jan 28, 2022 |
| FY2021 | Nov 30, 2018 | ($36.85M) | Jan 28, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | ($1.00B) | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | ($738.77M) | Jan 28, 2026 |
| FY2024 | Nov 30, 2023 | ($545.20M) | Jan 28, 2025 |
| FY2023 | Nov 30, 2022 | ($401.25M) | Feb 15, 2024 |
| FY2022 | Nov 30, 2021 | ($220.89M) | Feb 9, 2023 |
| FY2021 | Nov 30, 2020 | ($103.70M) | Jan 28, 2022 |
| FY2020 | Nov 30, 2019 | ($60.46M) | Feb 16, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | $246.96M | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | $110.00M | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | $54.63M | Jan 28, 2026 |
| FY2024 | Nov 30, 2022 | $64.47M | Jan 28, 2025 |
| FY2022 | Nov 30, 2021 | $80.51M | Feb 9, 2023 |
| FY2021 | Nov 30, 2020 | $119.36M | Jan 28, 2022 |
| FY2020 | Nov 30, 2019 | $34.82M | Feb 16, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | (3) | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | (2) | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | (2) | Jan 28, 2026 |
| FY2024 | Nov 30, 2022 | (3) | Jan 28, 2025 |
| FY2022 | Nov 30, 2021 | (2) | Feb 9, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | (3) | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | (2) | Jan 28, 2026 |
| FY2025 | Nov 30, 2023 | (2) | Jan 28, 2026 |
| FY2024 | Nov 30, 2022 | (3) | Jan 28, 2025 |
| FY2022 | Nov 30, 2021 | (2) | Feb 9, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | 101.81M | Jan 28, 2026 |
| FY2025 | Nov 30, 2024 | 75.87M | Jan 28, 2026 |
| FY2024 | Nov 30, 2023 | 48.72M | Jan 28, 2025 |
| FY2023 | Nov 30, 2022 | 47.17M | Feb 15, 2024 |
| FY2022 | Nov 30, 2021 | 44.66M | Feb 9, 2023 |
| FY2021 | Nov 30, 2020 | 38.86M | Jan 28, 2022 |
| FY2020 | Nov 30, 2019 | 3.60M | Feb 16, 2021 |